These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31677367)

  • 1. Modified release of furosemide from Eudragits® and poly(ethylene oxide)-based matrices and dry-coated tablets.
    Vlachou M; Geraniou E; Siamidi A
    Acta Pharm; 2020 Mar; 70(1):49-61. PubMed ID: 31677367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations.
    Vlachou M; Siamidi A; Dotsikas Y
    Curr Drug Deliv; 2019; 16(10):931-939. PubMed ID: 31663479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
    Hamza Yel-S; Aburahma MH
    Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of drug release from aged prolonged polyethylene oxide tablet matrices: effect of excipient and drug type.
    Shojaee S; Kaialy W; Cumming KI; Nokhodchi A
    Pharm Dev Technol; 2016 Mar; 21(2):189-95. PubMed ID: 25410967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of drug loading capacity of cellactose with two ad hoc processed lactose-cellulose direct compression excipients.
    Casalderrey M; Souto C; Concheiro A; Gómez-Amoza JL; Martínez-Pacheco R
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):398-401. PubMed ID: 15056951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
    Rasool BK; Fahmy SA; Galeel OW
    Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and evaluation of polymeric coated minitablets as multiple unit gastroretentive floating drug delivery systems for furosemide.
    Meka L; Kesavan B; Kalamata VN; Eaga CM; Bandari S; Vobalaboina V; Yamsani MR
    J Pharm Sci; 2009 Jun; 98(6):2122-32. PubMed ID: 19009598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression.
    Gulsun T; Ozturk N; Kaynak MS; Vural I; Sahin S
    Pharmazie; 2017 Jul; 72(7):389-394. PubMed ID: 29441935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system.
    Kumar RV; Sinha VR
    Acta Pharm; 2011 Sep; 61(3):343-51. PubMed ID: 21945913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Meth)acrylate copolymers of Eudragit® type in oral tablet technology.
    Naiserová M; Kubová K; Vysloužil J; Bernatoniene J; Brokalakis I; Vetchý D
    Ceska Slov Farm; 2019; 68(5):183-197. PubMed ID: 31896262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia.
    Cha KH; Park J; Cho W; Gu DG; Jeong K; Hwang SJ
    Arch Pharm Res; 2009 Nov; 32(11):1593-8. PubMed ID: 20091273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some factors affecting properties and dissolution behavior of tableted furosemide microspheres.
    Akbuğa J
    Pharmazie; 1992 Feb; 47(2):128-31. PubMed ID: 1635921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of hot-melt extrusion and injection molding for continuous manufacturing of immediate-release tablets.
    Melocchi A; Loreti G; Del Curto MD; Maroni A; Gazzaniga A; Zema L
    J Pharm Sci; 2015 Jun; 104(6):1971-1980. PubMed ID: 25761921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and Development of Novel Sulfasalazine Bilayer Tablets for The Treatment of Arthritis Associated With IBD: In-vitro and In-vivo Investigations.
    Jadiya S; Upmanyu N; Sathiyanarayanan A; Jain V; Dubey R; Buwade P
    J Pharm Sci; 2024 Jul; 113(7):1919-1926. PubMed ID: 38401631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilayer Tablet Formulation of Metformin HCl and Acarbose: A Novel Approach To Control Diabetes.
    Tiwari R; Gupta A; Joshi M; Tiwari G
    PDA J Pharm Sci Technol; 2014; 68(2):138-52. PubMed ID: 24668601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations.
    Kranz H; Wagner T
    Eur J Pharm Biopharm; 2006 Jan; 62(1):70-6. PubMed ID: 16154330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretic bioactivity optimization of furosemide in rats.
    Laulicht B; Tripathi A; Mathiowitz E
    Eur J Pharm Biopharm; 2011 Oct; 79(2):314-9. PubMed ID: 21571067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
    Riis T; Bauer-Brandl A; Wagner T; Kranz H
    Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies in preparation and evaluation of pH-independent sustained-release matrix tablets of verapamil HCl using directly compressible Eudragits.
    Gohel MC; Patel TP; Bariya SH
    Pharm Dev Technol; 2003; 8(4):323-33. PubMed ID: 14601957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of poly(ethylene oxide) in controlled release tablet systems: a review.
    Ma L; Deng L; Chen J
    Drug Dev Ind Pharm; 2014 Jul; 40(7):845-51. PubMed ID: 24001212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.